9p24.1 alterations and programmed cell death 1 ligand 1 expression in early stage unfavourable classical Hodgkin lymphoma: an analysis from the German Hodgkin Study Group NIVAHL trial
Zitieren Sie bitte immer diese URN: urn:nbn:de:bvb:20-opus-258358
- High programmed cell death 1 ligand 1 (PD-L1) protein expression and copy number alterations (CNAs) of the corresponding genomic locus 9p24.1 in Hodgkin- and Reed–Sternberg cells (HRSC) have been shown to be associated with favourable response to anti-PD-1 checkpoint inhibition in relapsed/refractory (r/r) classical Hodgkin lymphoma (cHL). In the present study, we investigated baseline 9p24.1 status as well as PD-L1 and major histocompatibility complex (MHC) class I and II protein expression in 82 biopsies from patients with early stageHigh programmed cell death 1 ligand 1 (PD-L1) protein expression and copy number alterations (CNAs) of the corresponding genomic locus 9p24.1 in Hodgkin- and Reed–Sternberg cells (HRSC) have been shown to be associated with favourable response to anti-PD-1 checkpoint inhibition in relapsed/refractory (r/r) classical Hodgkin lymphoma (cHL). In the present study, we investigated baseline 9p24.1 status as well as PD-L1 and major histocompatibility complex (MHC) class I and II protein expression in 82 biopsies from patients with early stage unfavourable cHL treated with anti-PD-1-based first-line treatment in the German Hodgkin Study Group (GHSG) NIVAHL trial (ClinicalTrials.gov Identifier: NCT03004833). All evaluated specimens showed 9p24.1 CNA in HRSC to some extent, but with high intratumoral heterogeneity and an overall smaller range of alterations than reported in advanced-stage or r/r cHL. All but two cases (97%) showed PD-L1 expression by the tumour cells in variable amounts. While MHC-I was rarely expressed in >50% of HRSC, MHC-II expression in >50% of HRSC was found more frequently. No obvious impact of 9p24.1 CNA or PD-L1 and MHC-I/II expression on early response to the highly effective anti-PD-1-based NIVAHL first-line treatment was observed. Further studies evaluating an expanded panel of potential biomarkers are needed to optimally stratify anti-PD-1 first-line cHL treatment.…
Autor(en): | Elena Gerhard-HartmannORCiD, Helen Goergen, Paul J. Bröckelmann, Anja Mottok, Tabea Steinmüller, Johanna Grund, Alberto Zamò, Susana Ben-Neriah, Stephanie Sasse, Sven Borchmann, Michael Fuchs, Peter Borchmann, Sarah Reinke, Andreas Engert, Johanna Veldman, Arjan Diepstra, Wolfram Klapper, Andreas Rosenwald |
---|---|
URN: | urn:nbn:de:bvb:20-opus-258358 |
Dokumentart: | Artikel / Aufsatz in einer Zeitschrift |
Institute der Universität: | Medizinische Fakultät / Pathologisches Institut |
Sprache der Veröffentlichung: | Englisch |
Titel des übergeordneten Werkes / der Zeitschrift (Englisch): | British Journal of Haematology |
Erscheinungsjahr: | 2022 |
Band / Jahrgang: | 196 |
Heft / Ausgabe: | 1 |
Seitenangabe: | 116–126 |
Originalveröffentlichung / Quelle: | British Journal of Haematology 2022, 196(1):116–126. DOI: 10.1111/bjh.17793 |
DOI: | https://doi.org/10.1111/bjh.17793 |
Allgemeine fachliche Zuordnung (DDC-Klassifikation): | 6 Technik, Medizin, angewandte Wissenschaften / 61 Medizin und Gesundheit / 610 Medizin und Gesundheit |
Freie Schlagwort(e): | CD274; classical Hodgkin lymphoma; fluorescence in situ hybridisation; immune checkpoint blockade; major histocompatibility complex |
Datum der Freischaltung: | 30.03.2022 |
Lizenz (Deutsch): | CC BY-NC-ND: Creative-Commons-Lizenz: Namensnennung, Nicht kommerziell, Keine Bearbeitungen 4.0 International |